Phase II prospective treatment study for IgG4+MOLPS

Phase II prospective treatment study for IgG4+MOLPS - IgG4 prospective treatment study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002311

Enrollment

Registered

2009-08-10

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgG4+MOLPS (IgG4+Multiorgan lymphoproliferative syndrome)

Interventions

Initial dose of prednisolone 0.6mg/kg/day. Taper prednisolone every 2 weeks 10%, and maintenance dose 10mg/day at least 3 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, IgG4+MOLPS 2, age more than 19 yrs 3, written informed consent

Exclusion criteria

Exclusion criteria: 1, Castleman disease, Wegener granulomatosis, Sarcoidosis, cancer lymphoma, and other distinct disorders. 2, severe infectious disease 3, pre-treatment of steroid or immuno-suppressive drugs 4, physician's decision

Design outcomes

Primary

Measure	Time frame
CR rate	—

Secondary

Measure	Time frame
Maintenance dose of steroid, relapse rate, adverse effects	—

Countries

Japan

Contacts

Public ContactYasufumi Masaki

Kanazawa Medical University Hematology and Immunology

yasum@kanazawa-med.ac.jp076-286-3511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026